136 related articles for article (PubMed ID: 22785554)
1. Initial high dose hydrocortisone (HDC) treatment for 21-hydroxylase deficiency (21-OHD) does not affect linear growth during the first three years of life.
Takasawa K; Ono M; Miyai K; Matsubara Y; Takizawa F; Onishi T; Kashimada K; Mizutani S
Endocr J; 2012; 59(11):1001-6. PubMed ID: 22785554
[TBL] [Abstract][Full Text] [Related]
2. Non-classical 21-hydroxylase deficiency in infancy and childhood: the effect of time of initiation of therapy on puberty and final height.
Weintrob N; Dickerman Z; Sprecher E; Galatzer A; Pertzelan A
Eur J Endocrinol; 1997 Feb; 136(2):188-95. PubMed ID: 9116914
[TBL] [Abstract][Full Text] [Related]
3. Growth pattern of untreated boys with simple virilizing congenital adrenal hyperplasia indicates relative androgen insensitivity during the first six months of life.
Bonfig W; Schwarz HP
Horm Res Paediatr; 2011; 75(4):264-8. PubMed ID: 21196707
[TBL] [Abstract][Full Text] [Related]
4. Final height in congenital adrenal hyperplasia: the dilemma of hypercortisolism versus hyperandrogenism.
Cordeiro GV; Silva IN; Goulart EM; Chagas AJ; Kater CE
Arq Bras Endocrinol Metabol; 2013 Mar; 57(2):126-31. PubMed ID: 23525290
[TBL] [Abstract][Full Text] [Related]
5. Treatment and disease effects on short-term growth and adult height in children and adolescents with 21-hydroxylase deficiency.
Hauffa BP; Winter A; Stolecke H
Klin Padiatr; 1997; 209(2):71-7. PubMed ID: 9113619
[TBL] [Abstract][Full Text] [Related]
6. Clinical, biochemical, and genetic features of non-classical 21-hydroxylase deficiency in Japanese children.
Kashimada K; Ishii T; Nagasaki K; Ono M; Tajima T; Yokota I; Hasegawa Y
Endocr J; 2015; 62(3):277-82. PubMed ID: 25736066
[TBL] [Abstract][Full Text] [Related]
7. Experience with long-term glucocorticoid treatment in congenital adrenal hyperplasia: growth pattern compared with genetic height potential.
Aycan Z; Ocal G; Berberoglu M; Cetinkaya E; Adiyaman P; Evliyaoglu O
J Pediatr Endocrinol Metab; 2006 Mar; 19(3):245-51. PubMed ID: 16607925
[TBL] [Abstract][Full Text] [Related]
8. Growth patterns in the first three years of life in children with classical congenital adrenal hyperplasia diagnosed by newborn screening and treated with low doses of hydrocortisone.
Bonfig W; Schmidt H; Schwarz HP
Horm Res Paediatr; 2011; 75(1):32-7. PubMed ID: 20714115
[TBL] [Abstract][Full Text] [Related]
9. Growth inhibition by glucocorticoid treatment in salt wasting 21-hydroxylase deficiency: in early infancy and (pre)puberty.
Stikkelbroeck NM; Van't Hof-Grootenboer BA; Hermus AR; Otten BJ; Van't Hof MA
J Clin Endocrinol Metab; 2003 Aug; 88(8):3525-30. PubMed ID: 12915631
[TBL] [Abstract][Full Text] [Related]
10. Early growth, pubertal development, body mass index and final height of patients with congenital adrenal hyperplasia: factors influencing the outcome.
Manoli I; Kanaka-Gantenbein Ch; Voutetakis A; Maniati-Christidi M; Dacou-Voutetakis C
Clin Endocrinol (Oxf); 2002 Nov; 57(5):669-76. PubMed ID: 12390343
[TBL] [Abstract][Full Text] [Related]
11. [Comparative study of prednisolone versus hydrocortisone acetate for treatment of patients with the classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency].
Leite FM; Longui CA; Kochi C; Faria CD; Borghi M; Calliari LE; Monte O
Arq Bras Endocrinol Metabol; 2008 Feb; 52(1):101-8. PubMed ID: 18345402
[TBL] [Abstract][Full Text] [Related]
12. Indicators of adult height outcome in classical 21-hydroxylase deficiency congenital adrenal hyperplasia.
Muirhead S; Sellers EA; Guyda H;
J Pediatr; 2002 Aug; 141(2):247-52. PubMed ID: 12183722
[TBL] [Abstract][Full Text] [Related]
13. Effect of the dose of oral hydrocortisone on growth rate during long-term treatment of children with salt losing congenital adrenal hyperplasia.
Ciaccio M; Montiveros C; Rivarola MA; Belgorosky A
Medicina (B Aires); 2002; 62(6):551-4. PubMed ID: 12532689
[TBL] [Abstract][Full Text] [Related]
14. Longitudinal analysis of growth and body composition of Japanese 21-OHD patients in childhood.
Matsubara Y; Ono M; Miyai K; Takizawa F; Takasawa K; Onishi T; Kashimada K; Mizutani S
Endocr J; 2013; 60(2):149-54. PubMed ID: 23018978
[TBL] [Abstract][Full Text] [Related]
15. Growth of patients with 21-hydroxylase deficiency: an analysis of the factors influencing adult height.
Jääskeläinen J; Voutilainen R
Pediatr Res; 1997 Jan; 41(1):30-3. PubMed ID: 8979286
[TBL] [Abstract][Full Text] [Related]
16. Adult height of subjects with nonclassical 21-hydroxylase deficiency.
Eyal O; Tenenbaum-Rakover Y; Shalitin S; Israel S; Weintrob N
Acta Paediatr; 2013 Apr; 102(4):419-23. PubMed ID: 23298233
[TBL] [Abstract][Full Text] [Related]
17. HYDROCORTISONE THERAPY AND GROWTH TRAJECTORY IN CHILDREN WITH CLASSICAL CONGENITAL ADRENAL HYPERPLASIA.
Bizzarri C; Improda N; Maggioli C; Capalbo D; Roma S; Porzio O; Salerno M; Cappa M
Endocr Pract; 2017 May; 23(5):546-556. PubMed ID: 28225306
[TBL] [Abstract][Full Text] [Related]
18. Growth analysis in patients with 21-hydroxylase deficiency influence of glucocorticoid dosage, age at diagnosis, phenotype and genotype on growth and height outcome.
Grigorescu-Sido A; Bettendorf M; Schulze E; Duncea I; Heinrich U
Horm Res; 2003; 60(2):84-90. PubMed ID: 12876419
[TBL] [Abstract][Full Text] [Related]
19. Hydrocortisone dosing during puberty in patients with classical congenital adrenal hyperplasia: an evidence-based recommendation.
Bonfig W; Pozza SB; Schmidt H; Pagel P; Knorr D; Schwarz HP
J Clin Endocrinol Metab; 2009 Oct; 94(10):3882-8. PubMed ID: 19622620
[TBL] [Abstract][Full Text] [Related]
20. Growth of patients with congenital adrenal hyperplasia due to 21-hydroxylase in infancy, glucocorticoid requirement and the role of mineralocorticoid therapy.
Sellick J; Aldridge S; Thomas M; Cheetham T
J Pediatr Endocrinol Metab; 2018 Sep; 31(9):1019-1022. PubMed ID: 30173205
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
